These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19833861)

  • 41. Effect of niacin on FGF23 concentration in chronic kidney disease.
    Rao M; Steffes M; Bostom A; Ix JH
    Am J Nephrol; 2014; 39(6):484-90. PubMed ID: 24854458
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairment.
    Wang YH; Liu F; Luk JA; Nirula A; Johnson-Levonas AO; Lasseter KC; Marbury TC; Lunde NM; Wagner JA; Lai E
    J Clin Pharmacol; 2011 Mar; 51(3):406-12. PubMed ID: 20484612
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The mechanism and mitigation of niacin-induced flushing.
    Kamanna VS; Ganji SH; Kashyap ML
    Int J Clin Pract; 2009 Sep; 63(9):1369-77. PubMed ID: 19691622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness and safety of laropiprant on niacin-induced flushing.
    Maccubbin DL; Chen F; Anderson JW; Sirah W; McCrary Sisk C; Kher U; Olsson AG; Bays HE; Mitchel YB
    Am J Cardiol; 2012 Sep; 110(6):817-22. PubMed ID: 22683042
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of prostaglandin D2 receptor antagonists based on a tetrahydropyridoindole scaffold.
    Beaulieu C; Guay D; Wang Z; Leblanc Y; Roy P; Dufresne C; Zamboni R; Berthelette C; Day S; Tsou N; Denis D; Greig G; Mathieu MC; O'Neill G
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2696-700. PubMed ID: 18359630
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The resurgence of niacin: from nicotinic acid to niaspan/laropiprant.
    Markel A
    Isr Med Assoc J; 2011 Jun; 13(6):368-74. PubMed ID: 21809737
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.
    Maccubbin D; Tipping D; Kuznetsova O; Hanlon WA; Bostom AG
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):582-9. PubMed ID: 20299362
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Niacin Promotes Cardiac Healing after Myocardial Infarction through Activation of the Myeloid Prostaglandin D
    Kong D; Li J; Shen Y; Liu G; Zuo S; Tao B; Ji Y; Lu A; Lazarus M; Breyer RM; Yu Y
    J Pharmacol Exp Ther; 2017 Mar; 360(3):435-444. PubMed ID: 28057839
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Short-term effects of extended-release niacin with and without the addition of laropiprant on endothelial function in individuals with low HDL-C: a randomized, controlled crossover trial.
    Nasser Figueiredo V; Vendrame F; Colontoni BA; Quinaglia T; Roberto Matos-Souza J; Azevedo Moura F; Coelho OR; de Faria EC; Sposito AC
    Clin Ther; 2014 Jun; 36(6):961-6. PubMed ID: 24768191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
    Renda G; Tacconelli S; Capone ML; Sacchetta D; Santarelli F; Sciulli MG; Zimarino M; Grana M; D'Amelio E; Zurro M; Price TS; Patrono C; De Caterina R; Patrignani P
    Clin Pharmacol Ther; 2006 Sep; 80(3):264-74. PubMed ID: 16952493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of multiple doses of clarithromycin on the pharmacokinetics of laropiprant in healthy subjects.
    Wang YH; Schwartz JI; Luo WL; Jumes P; Desai R; Wenning LA; Wagner JA; Lai E
    Cardiovasc Ther; 2011 Apr; 29(2):140-5. PubMed ID: 20337634
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Niacin and laropiprant.
    Sanyal S; Kuvin JT; Karas RH
    Drugs Today (Barc); 2010 Jun; 46(6):371-8. PubMed ID: 20571606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
    Haynes R; Valdes-Marquez E; Hopewell JC; Chen F; Li J; Parish S; Landray MJ; Armitage J; ; ;
    Clin Ther; 2019 Sep; 41(9):1767-1777. PubMed ID: 31447131
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus.
    Santilli F; Davì G; Consoli A; Cipollone F; Mezzetti A; Falco A; Taraborelli T; Devangelio E; Ciabattoni G; Basili S; Patrono C
    J Am Coll Cardiol; 2006 Jan; 47(2):391-7. PubMed ID: 16412866
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
    Rubenfire M;
    Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients.
    Kush D; Hu DY; Ye P; Kim HS; Chen E; Sirah W; McCrary Sisk C; Paolini JF; Maccubbin D
    Cardiology; 2009; 114(3):192-8. PubMed ID: 19602880
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study.
    DiChiara J; Bliden KP; Tantry US; Hamed MS; Antonino MJ; Suarez TA; Bailon O; Singla A; Gurbel PA
    Diabetes; 2007 Dec; 56(12):3014-9. PubMed ID: 17848625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.